Nothing said here yet.
to join the conversation.
| Dandekar AtulCSBO | Sell | 7,500 | $240.5K | Thu, Oct 29 |
| Coloma Jason VChief Executive Officer | Sell | 31,908 | $862.2K | Thu, Oct 1 |
| Bernstein HaroldPresident, R&D & CMO | Sell | 16,141 | $434.7K | Thu, Oct 1 |
| Coloma Jason VChief Executive Officer | Sell | 2,593 | $70.1K | Thu, Oct 1 |
| Dandekar AtulCSBO | Sell | 7,500 | $202.9K | Tue, Sep 29 |
| Bernstein HaroldPresident, R&D & CMO | Sell | 9,705 | $254.5K | Fri, Sep 4 |
| Coloma Jason VChief Executive Officer | Sell | 11,282 | $293.5K | Thu, Sep 3 |
| Bernstein HaroldPresident, R&D & CMO | Sell | 5,130 | $133.4K | Thu, Sep 3 |
| Dandekar AtulCSBO | Sell | 3,207 | $83.4K | Thu, Sep 3 |
| Courtney PhillipsGC and Corp. Secretary | Sell | 1,990 | $51.8K | Thu, Sep 3 |
| Coloma Jason VChief Executive Officer | Sell | 129 | $3.3K | Thu, Sep 3 |
| Bernstein HaroldPresident, R&D & CMO | Sell | 59 | $1.5K | Thu, Sep 3 |
Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE).
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals.
Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc.